Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due.
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 Akero Therapeutics, Inc. , a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high.
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.